[{"id":"0e9bd26b-0254-4ab8-9cad-e1d2a53d9952","acronym":"PRESERVE-003","url":"https://clinicaltrials.gov/study/NCT05671510","created_at":"2023-01-04T14:58:53.390Z","updated_at":"2025-02-25T12:38:29.772Z","phase":"Phase 3","brief_title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05671510 - PRESERVE-003","lead_sponsor":"OncoC4, Inc.","biomarkers":" LAG3 • CTLA4 • TIGIT","pipe":"","alterations":" ","tags":["LAG3 • CTLA4 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • gotistobart (BNT316)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"}]